Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

The 27-year-old woman had to have major brain surgery to correct a rare condition called Chiari Malformation, which means ...

The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

A new AI tool, MindGlide, can rapidly analyze routine brain MRI scans to detect subtle changes caused by multiple sclerosis ...

MindGlide is an AI tool from UCL that can help interpret and assess how well treatments are working for people with MS.

Researchers at UCL have developed an innovative AI tool called MindGlide, designed to transform the way MS treatments are ...

The actress boosts awareness of MS as the West Hollywood-based neurologist works to limit its effect on patients ...